Direct Healthcare Professional Communication (DHPC) on flucytosine: updated recommendations for the use in patients with dihydropyrimidine dehydrogenase (DPD) deficiency
2020.06.04
Active substance: Flucytosine
Mylan (Meda Pharma GmbH & Co KG), in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), would like to inform you that the treatment with flucytosine is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (DPD) deficiency due to the risk of life-threatening toxicity. Pre-treatment testing for DPD deficiency is however not required in order to avoid delay in antimycotic therapy.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN